JNJ-67856633 + ibrutinib

**JNJ-67856633 + ibrutinib** is an investigational **oral combination therapy** for hematologic malignancies combining two small-molecule inhibitors: JNJ-67856633 (also known as safimaltib), a potent and selective first-in-class inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1), and ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. JNJ-67856633 targets MALT1 allosterically to inhibit NF-κB signaling, while ibrutinib covalently and irreversibly inhibits BTK in B-cell receptor (BCR) signaling. This combination is being studied for **relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)** and **chronic lymphocytic leukemia (CLL)**, with the aim of improving outcomes by cotargeting parallel signaling pathways implicated in tumorigenesis and drug resistance[1][3][5][7].

Other names

JNJ-67856633 and ibrutinib combinationJNJ67856633 and ibrutinib combinationJNJ 67856633 and ibrutinib combinationsafimaltib and ibrutinib combination